Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral semaglutide in hyperglycaemic patients after renal transplantation
2023-504159-29-00Phase 2Withdrawn
- Sponsor
- Rigshospitalet
- Start
- Jul 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hyperglycemia comparing Oral semaglutide (Rybelsus) with Placebo (2 arms). Primary endpoint: Mean sensor glucose (mmol/L) evaluated by continuous glucose monitoring (CGM). Planned start Jul 2023; status: withdrawn.
02
Drugs
03
Conditions
hyperglycemia
Beyond the preview
Go deeper on 2023-504159-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504159-29-00.